Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 51543-39-6
2. (s)-flurbiprofen
3. (s)-(+)-2-fluoro-alpha-methyl-4-biphenylacetic Acid
4. (s)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanoic Acid
5. S-flurbiprofen
6. (2s)-2-(2-fluorobiphenyl-4-yl)propanoic Acid
7. Flurbiprofen, (s)-
8. (s)-2-(2-fluorobiphenyl-4-yl)propanoic Acid
9. Bts 24332
10. Bts-24332
11. Tt-063
12. J5zzk9p7mx
13. (2s)-2-(3-fluoro-4-phenylphenyl)propanoic Acid
14. (s)-2-fluoro-alpha-methyl-4-biphenylacetic Acid
15. Chembl435298
16. Chebi:42446
17. Esflurbiprofen (jan)
18. Esflurbiprofen [jan]
19. (s)-2-fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic Acid
20. Esflurbiprofene
21. Esflurbiprofeno
22. Esflurbiprofenum
23. Sfpp
24. Smr000471846
25. Esflurbiprofene [french]
26. Esflurbiprofenum [latin]
27. (s)-(+)-flurbiprofen
28. Esflurbiprofeno [spanish]
29. Unii-j5zzk9p7mx
30. Esflurbiprofen [inn:ban]
31. Flurwood
32. Urbifen
33. (+)-flurbiprofen
34. Flp
35. Einecs 257-263-1
36. Flurbiprofen-(s)-(+)
37. Esflurbiprofen [inn]
38. Zinc323
39. Mls001066337
40. Mls001333207
41. Mls001333208
42. Schembl505817
43. Gtpl9420
44. Esflurbiprofen [who-dd]
45. (s)-2-(2-fluoro-[1,1'-biphenyl]-4-yl)propanoicacid
46. Dtxsid201316678
47. Hms2232e18
48. Hms3649p05
49. Hms3884i06
50. Bcp24046
51. Bdbm50172479
52. Mfcd00866152
53. Nsc685700
54. S1679
55. Akos016844131
56. Ccg-266907
57. Nsc-685700
58. As-78108
59. Hy-15123
60. Nci60_030810
61. Nci60_030811
62. Db-008733
63. Cs-0003779
64. Sw202926-2
65. A21120
66. D10254
67. Sr-01000946685
68. (s)-(+)-2-fluoro-?-methyl-4-biphenylacetic Acid
69. Sr-01000946685-1
70. Q27104495
71. (s)-(+)-2-fluoro-.alpha.-methyl-4-biphenylacetic Acid
72. (2s)-2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic Acid
73. (s)-2-fluoro-.alpha.-methyl-4-biphenylacetic Acid
| Molecular Weight | 244.26 g/mol |
|---|---|
| Molecular Formula | C15H13FO2 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 244.08995782 g/mol |
| Monoisotopic Mass | 244.08995782 g/mol |
| Topological Polar Surface Area | 37.3 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 286 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
M - Musculo-skeletal system
M02 - Topical products for joint and muscular pain
M02A - Topical products for joint and muscular pain
M02AA - Antiinflammatory preparations, non-steroids for topical use
M02AA29 - Esflurbiprofen
(s)-flurbiprofen has known human metabolites that include 4-hydroxy-S-flurbiprofen.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 41440
Submission : 2025-03-11
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36747
Submission : 2022-10-17
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
About the Company : Hy-Gro Chemicals Pharmtek Pvt. Ltd. (Hy-Gro) is a fast growing pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Advanced Intermediates...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Contusions.
Lead Product(s): Esflurbiprofen,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2025
Lead Product(s) : Esflurbiprofen,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions
Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Contusions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2025
Details:
Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Esflurbiprofen,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 11, 2025
Lead Product(s) : Esflurbiprofen,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 11, 2025
Details:
Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ankle Injuries.
Lead Product(s): Esflurbiprofen,Inapplicable
Therapeutic Area: Orthopedics/Orthopedic Surgery Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2025
Lead Product(s) : Esflurbiprofen,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.
Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ankle Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2025
Details:
Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Esflurbiprofen,Flurbiprofen
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025
Lead Product(s) : Esflurbiprofen,Flurbiprofen
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2025
Details:
Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Soft Tissue Injuries.
Lead Product(s): Esflurbiprofen,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: ClinSearch | CRM Biometrics | Clinigen Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 01, 2021
Lead Product(s) : Esflurbiprofen,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : ClinSearch | CRM Biometrics | Clinigen Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain
Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Soft Tissue Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2021
Details:
Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Esflurbiprofen,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Teikoku Seiyaku | SocraMetrics GmbH
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 10, 2020
Lead Product(s) : Esflurbiprofen,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Teikoku Seiyaku | SocraMetrics GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet
Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 10, 2020
Details:
Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Lead Product(s): Esflurbiprofen,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 15, 2018
Lead Product(s) : Esflurbiprofen,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of SFPP in Knee Osteoarthritis
Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 15, 2018
Details:
Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ankle Injuries.
Lead Product(s): Esflurbiprofen,Inapplicable
Therapeutic Area: Orthopedics/Orthopedic Surgery Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 06, 2016
Lead Product(s) : Esflurbiprofen,Inapplicable
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain
Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ankle Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 06, 2016
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : The Zone
Dosage Form : Lozenge
Dosage Strength : 8.75mg
Packaging :
Approval Date : 04/12/2009
Application Number : 20071121000020
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : The Orange Strip
Dosage Form : Lozenge
Dosage Strength : 8.75mg
Packaging :
Approval Date : 18/10/2012
Application Number : 20110104000098
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Strefen Honey & Lemon
Dosage Form : Inhalation Spray
Dosage Strength : 16.2mg/ml
Packaging :
Approval Date : 18/11/2019
Application Number : 20180813000016
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Strefen Honey & Eucalyptus
Dosage Form : Lozenge
Dosage Strength : 8.75mg
Packaging :
Approval Date : 28/12/2021
Application Number : 20190125000017
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Strefen Cherry & Mint
Dosage Form : Inhalation Spray
Dosage Strength : 16.2mg/ml
Packaging :
Approval Date : 12/01/2018
Application Number : 20170316000033
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Deregistered
Registration Country : Sweden
Brand Name : Flurbiprofen Apelsin Reckitt Benckiser
Dosage Form : Lozenge
Dosage Strength : 8.75mg
Packaging :
Approval Date : 28/12/2021
Application Number : 20190125000024
Regulatory Info : Deregistered
Registration Country : Sweden
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Strepsils Dolo
Dosage Form : Lozenge
Dosage Strength : 8.75mg
Packaging :
Approval Date : 23/04/2009
Application Number : 58523
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Strepsils Dolo Orange
Dosage Form : Lozenge
Dosage Strength : 8.75mg
Packaging :
Approval Date : 08/12/2014
Application Number : 65201
Regulatory Info : Allowed
Registration Country : Switzerland
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Flurbiprofen Stada
Dosage Form : Inhalation Spray
Dosage Strength : 16.2mg/ml
Packaging :
Approval Date : 05/12/2024
Application Number : 20240430000056
Regulatory Info : Approved
Registration Country : Sweden
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Froben
Dosage Form : Tablet
Dosage Strength : 50mg
Packaging :
Approval Date : 13/09/1977
Application Number : 40795
Regulatory Info : Allowed
Registration Country : Switzerland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
APIs
Reply
27 Sep 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
88
PharmaCompass offers a list of Esflurbiprofen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Esflurbiprofen manufacturer or Esflurbiprofen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Esflurbiprofen manufacturer or Esflurbiprofen supplier.
PharmaCompass also assists you with knowing the Esflurbiprofen API Price utilized in the formulation of products. Esflurbiprofen API Price is not always fixed or binding as the Esflurbiprofen Price is obtained through a variety of data sources. The Esflurbiprofen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Esflurbiprofen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Esflurbiprofen, including repackagers and relabelers. The FDA regulates Esflurbiprofen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Esflurbiprofen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Esflurbiprofen manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Esflurbiprofen supplier is an individual or a company that provides Esflurbiprofen active pharmaceutical ingredient (API) or Esflurbiprofen finished formulations upon request. The Esflurbiprofen suppliers may include Esflurbiprofen API manufacturers, exporters, distributors and traders.
click here to find a list of Esflurbiprofen suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Esflurbiprofen DMF (Drug Master File) is a document detailing the whole manufacturing process of Esflurbiprofen active pharmaceutical ingredient (API) in detail. Different forms of Esflurbiprofen DMFs exist exist since differing nations have different regulations, such as Esflurbiprofen USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Esflurbiprofen DMF submitted to regulatory agencies in the US is known as a USDMF. Esflurbiprofen USDMF includes data on Esflurbiprofen's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Esflurbiprofen USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Esflurbiprofen suppliers with USDMF on PharmaCompass.
Esflurbiprofen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Esflurbiprofen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Esflurbiprofen GMP manufacturer or Esflurbiprofen GMP API supplier for your needs.
A Esflurbiprofen CoA (Certificate of Analysis) is a formal document that attests to Esflurbiprofen's compliance with Esflurbiprofen specifications and serves as a tool for batch-level quality control.
Esflurbiprofen CoA mostly includes findings from lab analyses of a specific batch. For each Esflurbiprofen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Esflurbiprofen may be tested according to a variety of international standards, such as European Pharmacopoeia (Esflurbiprofen EP), Esflurbiprofen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Esflurbiprofen USP).
Comment (3)
